EDN1 and chronic kidney disease: The RAS blocker [99,100], Dapagliflozin (sodium-glucose cotransporter 2 inhibitor) [101], Atrasentan (endothelin-1 blocker) [102], Tolvaptan (vasopressin receptor 2 antagonist) [103], Finerenone (non-steroidal anti-mineralocorticoid) [104] are found to delay the progression of CKD.